/ /

  • linkedin
  • Increase Font
  • Sharebar

    Sustained drug delivery moving toward clinical use


    Envisa Therapeutics

    Drug makers who want uniform tablets use molds; so do electronics manufacturers. Why not use miniature molds to create micro-size injectable rods that contain nano-sized drug particles?

    “Our technology is gentle enough that we can formulate very sensitive substances, such as DNA, monoclonal antibodies, even cyclosporine, to create clinically useful products,” said Chief Scientific Officer Benjamin Yerxa, PhD. “We can very precisely create microgram doses with the precise size, shape, and physical characteristics needed to ensure optimal therapeutic activity.”

    Trials of extended release prostaglandin in canines show an almost immediate response and a sustained 30% reduction in IOP over more than 120 days. Clinical trials are planned for later this year.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results